Crinetics Pharmaceuticals (CRNX) Q4 2024 earnings summary

Executive summary

• Achieved all 2024 objectives, including FDA acceptance of NDA for paltusotine in acromegaly and positive clinical results in carcinoid syndrome, CAH, and Cushing's disease; commercial and medical affairs teams expanded in the US and Europe, with new leadership appointments.

• Built a robust pipeline with 10 wholly-owned programs, four late-stage trials, and four IND filings planned for 2025.

• Strengthened balance sheet with $1.4B in cash and investments as of December 31, 2024, supporting operations into 2029.

• Leadership strengthened with new CFO, CCO, and senior VPs in clinical, medical, and oncology development.

Financial highlights

• Full-year 2024 revenue was $1.0M, down from $4.0M in 2023, primarily from licensing arrangements.

• R&D expenses rose to $240.2M for 2024 (from $168.5M in 2023), and SG&A/G&A expenses increased to $99.7M (from $58.1M), reflecting pipeline and commercial expansion.

• Net loss for 2024 was $298.4M, compared to $214.5M in 2023; Q4 2024 net loss was $80.6M.

• Ended 2024 with $1.4B in cash, cash equivalents, and investments, up from $558.6M at end of 2023.

Outlook and guidance

• Anticipates 2025 cash burn of $340–$380M, reflecting initiation of four late-stage trials and commercial launch preparations.

• NDA for paltusotine accepted by FDA; PDUFA date set for September 25, 2025; MAA filing in Europe planned for 1H2025.

• Four novel IND filings and multiple candidate selections expected in 2025.